ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Daiichi Sankyo to earn up to $7bn in AstraZeneca cancer drug deal

Japanese pharmaceutical receives testing and marketing muscle from global partner

TOKYO -- Daiichi Sankyo has entered into an agreement with AstraZeneca to cooperate in clinical trials and commercialization of a new anti-cancer drug that Daiichi Sankyo is developing, the Japanese pharmaceutical announced on Friday.

Through the deal, AstraZeneca will pay Daiichi Sankyo up to $6.9 billion.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more